FY2026 Earnings Estimate for Cryoport Issued By Roth Capital

Cryoport, Inc. (NASDAQ:CYRX) – Equities researchers at Roth Capital issued their FY2026 EPS estimates for shares of Cryoport in a research note issued to investors on Wednesday, March 5th. Roth Capital analyst R. Baldry forecasts that the company will earn ($1.23) per share for the year. The consensus estimate for Cryoport’s current full-year earnings is ($0.99) per share.

Several other research firms also recently commented on CYRX. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Cryoport in a research note on Wednesday. Guggenheim began coverage on shares of Cryoport in a report on Thursday, December 19th. They issued a “buy” rating and a $11.00 target price for the company. Finally, Roth Mkm lowered their price target on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Cryoport presently has an average rating of “Moderate Buy” and an average price target of $12.29.

Cryoport Price Performance

NASDAQ CYRX opened at $6.61 on Thursday. The business’s fifty day moving average is $7.34 and its 200 day moving average is $7.62. Cryoport has a fifty-two week low of $4.58 and a fifty-two week high of $20.10. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. The company has a market capitalization of $326.74 million, a PE ratio of -1.96 and a beta of 1.59.

Cryoport (NASDAQ:CYRX) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The business had revenue of $59.53 million for the quarter, compared to analysts’ expectations of $58.71 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same quarter in the prior year, the business earned ($0.29) EPS.

Institutional Investors Weigh In On Cryoport

A number of hedge funds have recently made changes to their positions in the company. Thematics Asset Management increased its stake in Cryoport by 176.2% in the 3rd quarter. Thematics Asset Management now owns 1,705,000 shares of the company’s stock worth $13,828,000 after acquiring an additional 1,087,800 shares during the last quarter. Fred Alger Management LLC increased its position in Cryoport by 49.9% in the third quarter. Fred Alger Management LLC now owns 2,698,768 shares of the company’s stock worth $21,887,000 after purchasing an additional 898,481 shares during the last quarter. Cadian Capital Management LP increased its position in Cryoport by 14.1% in the fourth quarter. Cadian Capital Management LP now owns 4,927,027 shares of the company’s stock worth $38,332,000 after purchasing an additional 609,021 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in Cryoport during the third quarter valued at $3,405,000. Finally, Millennium Management LLC lifted its position in Cryoport by 11.0% during the fourth quarter. Millennium Management LLC now owns 4,139,869 shares of the company’s stock valued at $32,208,000 after purchasing an additional 409,353 shares during the last quarter. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.